Engineering long-circulating deferoxamine targeting the innate immunity of neutrophil ferroptosis for systemic lupus erythematosus treatment.
文献摘要
Systemic lupus erythematosus (SLE) is characterized by dysregulation of both innate and adaptive immunity, in which ferroptosis-mediated neutrophil death has been implicated in disease progression. However, the clinical application of ferroptosis inhibitors remains limited by rapid systemic clearance and poor pharmacokinetic profiles. Here, we report a full positron emission tomography (PET)-guided strategy for pharmacokinetic engineering of ferroptosis inhibitors through albumin hitchhiking. By incorporating an albumin-binding motif into deferoxamine (DFO), we developed a series of albumin-hitchhiking conjugates and employed in vivo PET imaging-assisted evaluation to identify a long-circulating molecule, termed LAC NE . Blood pharmacokinetic analysis showed that LAC NE exhibited an estimated terminal blood half-life of 235.94 min, approximately 17-fold longer than that of DFO (13.74 min). Mechanistically, LAC NE was preferentially taken up by activated neutrophils via Fcγ receptor-mediated internalization under inflammatory conditions, resulting in effective suppression of neutrophil ferroptosis. Consequently, LAC NE reduced autoimmune responses, alleviated renal injury, and improved disease manifestations in lupus-prone mice. Collectively, these findings establish a PET-guided albumin-hitchhiking approach for pharmacokinetic optimization and targeted delivery of ferroptosis inhibitors, providing a promising strategy for precision treatment of SLE.